NCT00096941已完成2 期
An Open-Label, Multicenter Extension Study of Pertuzumab (rhuMAb 2C4) in Subjects Treated With Pertuzumab in a Previous Genentech-Sponsored Phase II Cancer Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 3
- 主要终点
- Percentage of Participants Who Experienced an Adverse Event
研究概览
简要总结
This is a multicenter, open label extension study. Subjects who have completed treatment in the parent study of pertuzumab, either alone or with a combination agent, and who received at least one dose of pertuzumab in the parent study are eligible for inclusion in this trial if they are continuing to receive clinical benefit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •ECOG performance status of 0, 1, or 2
- •Completion of treatment in a previous Genentech sponsored, Phase II cancer study with pertuzumab, either alone or with a combination agent, in which at least one dose of pertuzumab was received in the parent study
- •Less than 3 months since last dose of pertuzumab on the parent study
- •Use of an effective means of contraception for men or for women of childbearing potential
- •Granulocyte count >= 1500/uL
- •Platelet count >= 75,000/uL
- •Hemoglobin >= 9 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors; darbepoetin [Aranesp(R)] is permitted)
- •Serum bilirubin less than or equal to the upper limit of normal (ULN) (unless due to Gilbert's disease)
- •Alkaline phosphatase, AST, and ALT <= 2.5x ULN (<= 5x ULN for subjects with liver metastases; no alkaline phosphatase upper limit for subjects with bone metastases)
- •Serum creatinine <= 1.5x ULN
- •International normalized ratio (INR) < 1.5 and activated partial thromboplastin time (aPTT) < 1.5x ULN (except for subjects receiving warfarin)
排除标准
- •Recent (within the last 3 months), current, or planned participation in a experimental drug study other than a Genentech-sponsored pertuzumab cancer study
- •Any unresolved or irreversible NCI-CTC Grade 3 or 4 adverse event or clinically meaningful cardiac adverse event (any grade) that is pertuzumab-related and ongoing from the parent study
- •Recent (within the last 3 months) or current treatment with HER pathway inhibitors other than pertuzumab (e.g., Herceptin(R) [Trastuzumab], Iressa<TM> [gefitinib], Tarceva<TM> [erlotinib hydrochloride], C225, CI1033, or TAK165) or other monoclonal antibodies
- •Clinical evidence of central nervous system or brain metastases
- •Ejection fraction ≤50%, as determined by ECHO (or MUGA)
- •Uncontrolled hypercalcemia (> 11.5 mg/dL)
- •Recent anthracycline exposure (within the last 3 months) or cumulative exposure of > 360 mg/m^2 doxorubicin or equivalent (i.e., liposomal doxorubicin, > 120 mg/m^2 mitoxantrone, or > 90 mg/m^2 idarubicin)
- •Ongoing corticosteroid use (except for subjects who are on stable doses of < 20 mg of prednisone daily [or equivalent] or who are taking corticosteroids for reasons other than cancer)
- •Other malignancies (except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, or basal or squamous cell skin cancer)
- •Serious systemic disease, including active infection, uncontrolled hypertension (diastolic blood pressure > 100 mmHg on two consecutive occasions), unstable angina, congestive heart failure, or myocardial infarction or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia [i.e., atrial fibrillation], paroxysmal supraventricular tachycardia, or controlled hypertension are eligible)
- •Liver disease (including viral or other hepatitis), current alcohol abuse, or cirrhosis
- •Known human immunodeficiency virus infection
- •Pregnancy or lactation
- •Major surgery or significant traumatic injury within 3 weeks prior to Day 1
- •Inability to comply with study and follow-up procedures
- •Any diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the continued use of an investigational drug or that may render the subject at high risk from treatment complications
研究组 & 干预措施
Pertuzumab
Experimental
Participants received the same dose of pertuzumab that they received in their parent Phase II trial, either 420 mg or 1050 mg, intravenously on Day 1 of every 3 week cycle until disease progression.
干预措施: Pertuzumab (Drug)
结局指标
主要结局
Percentage of Participants Who Experienced an Adverse Event
时间窗: Baseline to the end of the study (up to 2 years, 5 months)
次要结局
- Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)(Baseline to the end of the study (up to 2 years, 5 months))
研究者
相似试验
进行中（未招募）
3 期
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyCancerNCT03768063Hoffmann-La Roche1,000
终止
2 期
Guadecitabine Extension StudyMyeloid Dysplastic SyndromeAcute Myeloid LeukemiaNCT03603964Astex Pharmaceuticals, Inc.35
已完成
4 期
Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis SubjectsRheumatoid ArthritisNCT00252668Wyeth is now a wholly owned subsidiary of Pfizer300
已完成
3 期
A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual BleedingMenorrhagiaNCT01280981Ferring Pharmaceuticals288
已完成
2 期
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary HyperparathyroidismHyperparathyroidism, PrimaryNCT00936988Amgen45